Barrett’s Esophagus Classification Using Multiplexed Fluorescence Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting the progression of Barrett's esophagus to esophageal adenocarcinoma are limited by inter-observer variation in histologic evaluation and the lack of reliable biomarkers for risk prediction, making it difficult to identify patients who require therapeutic intervention.
Innovation Solution
A tissue systems pathology approach using multiplexed fluorescence biomarker labeling and digital imaging to quantify molecular and cellular features, integrating image analysis features into a multivariable classifier for risk stratification, which includes detecting biomarkers such as p53, HIF-1α, COX-2, p16, AMACR, CD68, CD45RO, and K20, and analyzing image features like p53 nuclear sum intensity and COX2 texture to generate a prognostic score.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If histologic evaluation of esophageal biopsies is performed, then diagnosis of Barrett's esophagus can be made, but inter-observer variation and random endoscopic sampling limit the accuracy and reliability of the diagnosis
Solution Approach 1:
The patent replaces subjective mechanical histologic evaluation with objective digital image analysis. Automated algorithms quantify biomarker expression levels, cellular morphology, and tissue architecture from digital images, eliminating inter-observer variation and providing reproducible, quantitative diagnostic criteria that improve both accuracy and reliability.
Solution Approach 2:
The patent transforms qualitative histologic parameters into quantitative measurements. By measuring biomarker intensity, cellular dimensions, and spatial distributions through digital imaging, the system converts subjective pathologic assessments into objective numerical data that can be reliably reproduced and compared across different observers and time points.
2Measurement precision
If multiple biomarkers are detected using multiplexed fluorescence labeling, then risk prediction accuracy is improved, but device complexity and analytical difficulty increase
Solution Approach 1:
The patent combines multiple biomarker detections into a single integrated analysis system. By multiplexing fluorescence labels for different biomarkers on the same tissue section and analyzing them together through automated image analysis, the system achieves comprehensive risk assessment while managing complexity through unified processing rather than separate tests.
Solution Approach 2:
The automated image analysis system serves multiple functions simultaneously: it quantifies different biomarkers, assesses cellular morphology, evaluates tissue architecture, and generates risk predictions. This multi-functional approach consolidates what would otherwise require multiple separate systems into a single integrated platform.
3Reliability
If quantitative image analysis of multiple biomarkers is performed, then objective risk stratification is achieved, but measurement and analysis difficulty increases
Solution Approach 1:
The patent replaces complex manual measurement and subjective interpretation with automated digital image analysis algorithms. The system automatically detects, quantifies, and integrates multiple biomarker signals and morphologic features, eliminating the need for manual measurements and providing consistent, reproducible risk stratification that reduces analytical difficulty through automation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method accurately predicts the risk of progressing to high-grade dysplasia or esophageal adenocarcinoma, overcoming limitations of random sampling and subjective diagnoses, enabling earlier detection and treatment.
Implementation Method 1
multiplexed fluorescence biomarker labeling with digital imaging and image analysis to objectively quantify multiple epithelial and stromal biomarkers and morphology
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
Embodiments described herein provide methods of determining a risk of progression of Barrett's esophagus in a subject, classifying Barrett's esophagus in a subject, and detecting a field effect associated with malignant transformation of an esophagus of a subject suffering from Barrett's esophagus. The disclosure also provides kits for determining a risk of progression of Barrett's esophagus in a subject and classifying Barrett's esophagus in a subject.